A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Pancreatic beta cells sense blood glucose via glucokinase and trigger insulin secretion when glucose rises above ~100 mg/dL, with the insulin response amplified by amino acids, fatty acids, and gastrointestinal hormones (incretins). Insulin promotes glucose uptake, glycogenesis, and protein synthesis while inhibiting gluconeogenesis and lipolysis in target tissues.
From your study of the endocrine system, you know that hormones are secreted by endocrine cells in response to specific stimuli and act on distant target tissues. The pancreatic beta cell is a beautifully engineered glucose sensor — its insulin secretion rate is directly proportional to blood glucose concentration, making it the centerpiece of the body's glucose homeostasis system. Understanding how the beta cell converts a change in blood glucose into a precisely graded insulin signal requires following a molecular chain of events often called the stimulus-secretion coupling pathway.
The chain begins with glucose entering the beta cell through GLUT2 transporters, which have a high capacity and low affinity — meaning they transport glucose at a rate proportional to blood glucose concentration, without saturating at physiological levels. Inside the cell, glucokinase phosphorylates glucose to glucose-6-phosphate, committing it to glycolysis. Glucokinase is the rate-limiting step and the true glucose sensor: its Km of about 8 mM (144 mg/dL) means that its activity increases steeply across the physiological glucose range. As glucose is metabolized through glycolysis and oxidative phosphorylation, the intracellular ATP/ADP ratio rises. This rising ATP closes ATP-sensitive potassium channels (KATP channels) on the cell membrane. With potassium efflux blocked, the membrane depolarizes. Depolarization opens voltage-gated calcium channels, and the resulting influx of Ca2+ triggers exocytosis of insulin-containing secretory granules. The elegance of this design is that each step is proportional: more glucose means more ATP, more KATP closure, more depolarization, more calcium entry, and more insulin release.
The beta cell response is amplified by several additional signals. Incretins — gut hormones such as GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic peptide) — are released from intestinal cells when food arrives in the gut. They bind receptors on beta cells and raise cAMP, which potentiates insulin secretion at any given glucose level. This is why an oral glucose load produces a larger insulin response than the same amount of glucose given intravenously — a phenomenon called the incretin effect. Amino acids (especially leucine and arginine) and fatty acids also amplify secretion through metabolic and receptor-mediated pathways, ensuring that insulin responds not just to carbohydrate but to the full nutrient profile of a meal.
Once released, insulin binds to insulin receptors (receptor tyrosine kinases) on target cells — primarily liver, skeletal muscle, and adipose tissue. In muscle and fat, insulin stimulates translocation of GLUT4 transporters to the cell surface, dramatically increasing glucose uptake. In the liver, insulin activates glycogen synthase (promoting glycogen storage), upregulates glycolysis and lipogenesis, and suppresses gluconeogenesis and glycogenolysis. The net effect is to clear glucose from the blood and store it as glycogen and fat. As blood glucose falls back toward its set point (~90 mg/dL fasting), the stimulus for insulin secretion diminishes, KATP channels reopen, and insulin release tapers off — a classic negative feedback loop. Disruption at any step — beta cell destruction (type 1 diabetes), beta cell exhaustion, or target tissue insulin resistance (type 2 diabetes) — breaks this loop and produces sustained hyperglycemia.